Evaluating AKR1B10 as a marker for liver cancer treatment effectiveness
Evaluation of AKR1B10 as a New Marker for Interventional Therapy of Hepatocellular Carcinoma
This study is testing if a new blood marker called AKR1B10 can help doctors see how well treatments are working for patients with liver cancer who are receiving a specific type of therapy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Hebei Medical University Third Hospital Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Shijia Zhuang, Hebei) |
| Trial ID | NCT06272656 on ClinicalTrials.gov |
What this trial studies
This study investigates the clinical value of AKR1B10 as a serum marker for evaluating the efficacy of treatments in patients with hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE). The research involves measuring AKR1B10 levels in patients and comparing its performance against traditional biomarkers like AFP. The goal is to determine if AKR1B10 can provide more accurate and timely assessments of treatment response, potentially improving patient outcomes. The study includes a diverse cohort of individuals with varying liver conditions to establish the marker's diagnostic capabilities.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 80 diagnosed with hepatocellular carcinoma who are scheduled for TACE and cannot undergo surgical resection.
Not a fit: Patients with a history of other tumors or those who have received prior external treatments may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate monitoring of liver cancer treatment efficacy, improving patient management and outcomes.
How similar studies have performed: While the use of AKR1B10 as a biomarker is being explored, its application in this context is relatively novel and has not been extensively tested in previous studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * age between 18 and 80 * diagnosis of HCC according the AASLD criteria * TACE is planned * resection is impossible * No significant underlying medical illness affecting patient's survival * Patients available for regular follow-up according to the study protocol Exclusion Criteria: * Previous history of other tumors; * Combined with other tumors; * Received external treatment before admission; * Patients who have received blood transfusions within one month; * The patient was unable to participate in this study for other reasons.
Where this trial is running
Shijia Zhuang, Hebei
- HebeiMUTH — Shijia Zhuang, Hebei, China (Recruiting)
Study contacts
- Principal investigator: Yuemin Nan — Hebei Medical University Third Hospital
- Study coordinator: Yuemin Nan
- Email: Hb20231221@163.com
- Phone: 17835683894
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.